Background: In clinical studies, imiquimod 3.75% was shown to detect and treat actinic keratosis (AK) lesions across an entire sun-exposed field such as the full face or balding scalp. The aim of this study was to evaluate imiquimod 3.75% in a real-life clinical setting.
Methods: Ten AK patients applied imiquimod 3.75% to the full face or scalp once-daily in two 2-week treatment cycles separated by a two-week treatment-free interval and were followed-up eight weeks later. Seven patients rated imiquimod 3.75% versus prior treatments (cryotherapy, photodynamic therapy, diclofenac sodium 3%, imiquimod 5%, ingenol mebutate).
Results: The median clinical lesion count at baseline was 12.5. This increased to a median Lmax (maximum lesion count during treatment) of 22.5 as imiquimod 3.75% unmasked previously invisible subclinical lesions. At final follow-up, the median lesion count was 0. Local skin reactions such as erythema, scabbing and erosion occurred during each treatment cycle and were easy to manage. All patients considered imiquimod 3.75% easier to apply than prior treatments and 5 reported fewer or similar side effects.
Conclusions: In this cohort, imiquimod 3.75% effectively cleared clinical and subclinical lesions across the entire affected field and was well tolerated.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.23736/S0392-0488.17.05043-X | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Topical Calcipotriol Plus 5-Fluorouracil in the Treatment of Actinic Keratosis, Bowen's Disease, and Squamous Cell Carcinoma: A Systematic Review.
J Cutan Med Surg
September 2024
Department of Dermatology, Alfred Health, Melbourne, VIC, Australia.
Background/objectives: Actinic keratoses (AK) are premalignant skin lesions caused by chronic sun exposure, topically managed by 5-fluorouracil (5-FU), diclofenac 3% gel, and imiquimod. Despite their effectiveness, long treatment duration and severe adverse local skin reactions have limited patient concordance. Calcipotriol has recently been used as a combination agent for existing topical AK treatments.
View Article and Find Full Text PDFLaser-assisted nanocarrier delivery to achieve cutaneous siRNA targeting for attenuating psoriasiform dermatitis.
J Control Release
July 2022
Pharmaceutics Laboratory, Graduate Institute of Natural Products, Chang Gung University, Kweishan, Taoyuan, Taiwan; Research Center for Food and Cosmetic Safety and Research Center for Chinese Herbal Medicine, Chang Gung University of Science and Technology, Kweishan, Taoyuan, Taiwan; Department of Anesthesiology, Chang Gung Memorial Hospital, Kweishan, Taoyuan, Taiwan. Electronic address:
Psoriasis is an autoimmune skin disorder presenting the excessive expression of interleukin (IL)-6. The topical use of small interfering RNA (siRNA) has been increasingly discovered for treating skin diseases. A delivery system capable of protecting siRNA while facilitating both skin targeting and cellular entrance is critical for the successful medication of topically-applied siRNA.
View Article and Find Full Text PDFSARS-CoV-2 Infection Induces Psoriatic Arthritis Flares and Enthesis Resident Plasmacytoid Dendritic Cell Type-1 Interferon Inhibition by JAK Antagonism Offer Novel Spondyloarthritis Pathogenesis Insights.
Front Immunol
May 2021
Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom.
Objective: Bacterial and viral infectious triggers are linked to spondyloarthritis (SpA) including psoriatic arthritis (PsA) development, likely dendritic cell activation. We investigated spinal entheseal plasmacytoid dendritic cells (pDCs) toll-like receptor (TLR)-7 and 9 activation and therapeutic modulation, including JAK inhibition. We also investigated if COVID-19 infection, a potent TLR-7 stimulator triggered PsA flares.
View Article and Find Full Text PDFCD100-Plexin-B2 Promotes the Inflammation in Psoriasis by Activating NF-κB and the Inflammasome in Keratinocytes.
J Invest Dermatol
February 2018
Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, China; Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China. Electronic address:
PlxnB2 and its ligand, CD100, were originally identified as axon-guidance molecules that function during neuronal development; however, studies also showed that CD100-plexins participate in various immune responses. In this study, we found that the expression of PlxnB2 on keratinocytes was specifically increased in lesional skin of psoriasis patients but not atopic dermatitis. Levels of soluble CD100 and membrane-bound CD100 were elevated in sera of psoriasis patients and on keratinocytes of psoriatic skin, respectively.
View Article and Find Full Text PDFPatients' perceptions of topical treatments of actinic keratosis.
J Dermatolog Treat
October 2014
Department of Dermatology, Roskilde Hospital, Faculty of Health Sciences, University of Copenhagen, Roskilde , Denmark.
Objectives: In recent years, a number of topical treatments suitable for field-directed therapy of actinic keratosis (AK) have been developed. Non-surgical treatment of AK however requires strict adherence by patients. Patients' views on the different possible topical treatments are therefore relevant to the choice of treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!